‹ ›
MYP_058539
← PREVIOUS NEXT → BACK
Basic Information
HR2-14
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
34 amino acids
C165H283N47O56
Standard
Sequence
INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK
Physicochemical Analysis
3821.29 Da
4.66
-2.23
-2.44
-0.0656
-0.31
0.70
-0.06
44.50
134.71
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1729.47
-17.60
56.0
54.0
138.0
268.0
0.0
40.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0119281 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | 293T/ACE2 cells
0.947±0.179 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperDesign of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y. | J Virol. 2020 Jul 1;94(14):e00635-20. | DOI:10.1128/JVI.00635-20 | PMID:32376627 PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
RECORD: Rec_0119827 VERIFIED: YES
Provenance & Taxonomy
Severe acute respiratory syndrome-related coronavirus [Virus]
Heptad repeat peptide
694009;0
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Entry inhibitor Fusion inhibitor
SARS coronavirus (Virus entry); 293T
Luciferase assay
PaperSuppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. | Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X, Jiang P, Hu J, Xiong Z, Nie Y, Shi X, Wang W, Ling C, Yin X, Fan K, Lai L, Ding M, Deng H. | Biochem Biophys Res Commun. 2004 | PMID:15184046 PMID15184046 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15184046/
RECORD: Rec_0124150 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
SARS-CoV PsV
PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
RECORD: Rec_0125501 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
SARS-CoV-2:inhibition of cell-cell fusion in 293T/ACE2 cells
0.015±0.002 μM
IC50
PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
RECORD: Rec_0162453 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | 293T/ACE2 cells
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperDesign of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y. | J Virol. 2020 Jul 1;94(14):e00635-20. | DOI:10.1128/JVI.00635-20 | PMID:32376627 PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 2 of 4